喹诺酮耐药性大肠埃希菌临床分离株中parC基因突变的检测
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.
作者信息
Vila J, Ruiz J, Goñi P, De Anta M T
机构信息
Department of Microbiology, University of Barcelona, Spain.
出版信息
Antimicrob Agents Chemother. 1996 Feb;40(2):491-3. doi: 10.1128/AAC.40.2.491.
Abstract
The gene parC encodes the A subunit of topoisomerase IV of Escherichia coli. Mutations in the parC region analogous to those in the quinolone resistance-determining region of gyrA were investigated in 27 clinical isolates of E. coli for which ciprofloxacin MICs were 0.0007 to 128 micrograms/ml. Of 15 isolates for which ciprofloxacin MICs were > or = 1 microgram/ml, 8 showed a change in the serine residue at position 80 (Ser-80), 4 showed a change in Glu-84, and 3 showed changes in both amino acids. No mutations were detected in 12 clinical isolates for which ciprofloxacin MICs were < or = 0.25 micrograms/ml. These findings suggest that ParC from E. coli may be another target for quinolones and that mutations at residues Ser-80 and Glu-84 may contribute to decreased fluoroquinolone susceptibility.
摘要
基因parC编码大肠杆菌拓扑异构酶IV的A亚基。在环丙沙星MIC为0.0007至128微克/毫升的27株临床分离大肠杆菌中，研究了parC区域与gyrA喹诺酮耐药决定区域类似的突变。在环丙沙星MIC≥1微克/毫升的15株分离株中，8株在第80位丝氨酸残基（Ser-80）处有变化，4株在Glu-84处有变化，3株在这两个氨基酸处均有变化。在环丙沙星MIC≤0.25微克/毫升的12株临床分离株中未检测到突变。这些发现表明，大肠杆菌的ParC可能是喹诺酮类药物的另一个靶点，并且Ser-80和Glu-84残基处的突变可能导致氟喹诺酮敏感性降低。
相似文献
1
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.
Antimicrob Agents Chemother. 1996 Feb;40(2):491-3. doi: 10.1128/AAC.40.2.491.
2
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
3
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.
Antimicrob Agents Chemother. 1996 Apr;40(4):879-85. doi: 10.1128/AAC.40.4.879.
4
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
5
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
Antimicrob Agents Chemother. 1996 Mar;40(3):710-14. doi: 10.1128/AAC.40.3.710.
6
Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii.
J Antimicrob Chemother. 1997 Jun;39(6):757-62. doi: 10.1093/jac/39.6.757.
7
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
Microb Drug Resist. 2001 Spring;7(1):47-53. doi: 10.1089/107662901750152783.
8
Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.
Antimicrob Agents Chemother. 1996 Jul;40(7):1741-4. doi: 10.1128/AAC.40.7.1741.
9
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):61-4. doi: 10.1016/s0732-8893(99)00121-2.
10
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
引用本文的文献
1
Comparative Analysis of Phenotypic and Genotypic Antibiotic Susceptibility of Isolated from Various Host Species in France and Hungary.
Antibiotics (Basel). 2025 Sep 8;14(9):906. doi: 10.3390/antibiotics14090906.
2
Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.
Angew Chem Int Ed Engl. 2025 Mar 3;64(10):e202414325. doi: 10.1002/anie.202414325. Epub 2025 Feb 10.
3
Isolation, Characterization, and Complete Genome Sequence of Escherichia Phage KIT06 Which Infects Nalidixic Acid-Resistant .
Antibiotics (Basel). 2024 Jun 23;13(7):581. doi: 10.3390/antibiotics13070581.
4
Characterization of Transferrable Mechanisms of Quinolone Resistance (TMQR) among Quinolone-resistant Escherichia coli and Klebsiella pneumoniae causing Urinary Tract Infection in Nepalese Children.
BMC Pediatr. 2023 Sep 13;23(1):458. doi: 10.1186/s12887-023-04279-5.
5
High Carriage of Extended-Spectrum, Beta Lactamase-Producing, and Colistin-Resistant Enterobacteriaceae in Tibetan Outpatients with Diarrhea.
Antibiotics (Basel). 2022 Apr 11;11(4):508. doi: 10.3390/antibiotics11040508.
6
Effects of fluoroquinolones and tetracyclines on mitochondria of human retinal MIO-M1 cells.
Exp Eye Res. 2022 Jan;214:108857. doi: 10.1016/j.exer.2021.108857. Epub 2021 Nov 29.
7
Donnan Potential across the Outer Membrane of Gram-Negative Bacteria and Its Effect on the Permeability of Antibiotics.
Antibiotics (Basel). 2021 Jun 11;10(6):701. doi: 10.3390/antibiotics10060701.
8
Antimicrobial Resistance Glides in the Sky-Free-Living Birds as a Reservoir of Resistant With Zoonotic Potential.
Front Microbiol. 2021 Apr 9;12:656223. doi: 10.3389/fmicb.2021.656223. eCollection 2021.
9
Evolution of Antibiotic Resistance in Surrogates of (LVS and ): Effects on Biofilm Formation and Fitness.
Front Microbiol. 2020 Oct 30;11:593542. doi: 10.3389/fmicb.2020.593542. eCollection 2020.
10
High prevalence of mcr-1-encoded colistin resistance in commensal Escherichia coli from broiler chicken in Bangladesh.
Sci Rep. 2020 Oct 29;10(1):18637. doi: 10.1038/s41598-020-75608-2.
本文引用的文献
1
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.
Antimicrob Agents Chemother. 1993 Jun;37(6):1247-52. doi: 10.1128/AAC.37.6.1247.
2
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.
Antimicrob Agents Chemother. 1993 Apr;37(4):696-701. doi: 10.1128/AAC.37.4.696.
3
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.
J Biol Chem. 1993 Nov 15;268(32):24481-90.
4
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus.
Antimicrob Agents Chemother. 1993 Dec;37(12):2588-92. doi: 10.1128/AAC.37.12.2588.
5
Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro.
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8571-5. doi: 10.1073/pnas.90.18.8571.
6
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
7
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
Antimicrob Agents Chemother. 1994 Nov;38(11):2623-7. doi: 10.1128/AAC.38.11.2623.
8
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.
Antimicrob Agents Chemother. 1994 Oct;38(10):2477-9. doi: 10.1128/AAC.38.10.2477.
9
Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.
Mol Microbiol. 1994 Oct;14(2):371-80. doi: 10.1111/j.1365-2958.1994.tb01297.x.
10
Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.
Antimicrob Agents Chemother. 1995 May;39(5):1201-3. doi: 10.1128/AAC.39.5.1201.
Zotero 插件